Experts from Wiley discuss a strategy-driven approach to Medical Education, powered by timely, credible information delivered in multiple formats.
This series of the Elevate Podcast illuminates how AI and Generative AI seem to be a part of every webinar, conference, and conversation these days. This podcast will explore three proof-of-concept (POC) use cases from recent work in the field of Medical Information.
Medical Affairs is uniquely positioned as the only department capable of impacting the Enterprise Commercialization Process (ECP) at every stage, from the initial product concept through the entire commercialization effort.
This article explores how Sumitomo Pharma America (SMPA) leveraged H1’s advanced data capabilities to integrate diverse insights, enhance field medical strategies, and foster cross-functional collaboration across therapeutic areas.
This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
Regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.
Consequently, Pharma companies are increasingly including real-world studies in their evidence to:
• Understand the opportunities and best practices for involving patient partners in the generation of real-world evidence
• Explore, using case studies, the value of patient engagement in the design, delivery, analysis and communication of real-world studies
• Highlight the importance of Medical Affairs and Health Economics and Outcomes Research (HEOR) professionals in partnering with colleagues from different functions in Pharma to ensure patients are effectively engaged throughout the product lifecycle
• Discuss barriers and propose solutions to optimal patient engagement in real-world studies
Experts from Pfizer and Veeva explore a recent Veeva Pulse Report showing that targeted scientific outreach is associated with 40% faster treatment adoption.
We’ve developed real-time software that MA HQ and MSLs are already using daily to improve their physician insights, tailor field deployment and education, and track impact at the national, local, and individual physician level.
In this podcast, experts explore the many challenges associated with the operationalization of global Integrated Evidence Generation Planning (IEGP) at local levels.Â